Momenta Pharmaceuticals (NASDAQ:MNTA)‘s stock had its “buy” rating reaffirmed by research analysts at Stifel Nicolaus in a research note issued on Tuesday, AnalystRatings.com reports.
MNTA has been the subject of several other reports. HC Wainwright boosted their price objective on Momenta Pharmaceuticals from to and gave the company a “buy” rating in a report on Tuesday, February 4th. BidaskClub upgraded Momenta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, December 11th. Cantor Fitzgerald reissued a “neutral” rating and set a $30.00 price target (up from $22.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, February 26th. SunTrust Banks upped their price objective on shares of Momenta Pharmaceuticals to and gave the stock a “buy” rating in a report on Wednesday, January 15th. Finally, JPMorgan Chase & Co. raised shares of Momenta Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the company from $14.00 to $30.00 in a research note on Tuesday, January 14th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $35.00.
NASDAQ MNTA traded up $0.97 during mid-day trading on Tuesday, reaching $29.75. 1,252,043 shares of the company’s stock traded hands, compared to its average volume of 1,358,485. Momenta Pharmaceuticals has a 1-year low of $9.51 and a 1-year high of $34.83. The company has a fifty day simple moving average of $28.15 and a 200-day simple moving average of $21.63. The company has a market cap of $3.49 billion, a price-to-earnings ratio of -10.19 and a beta of 1.56.
In other Momenta Pharmaceuticals news, Director Elizabeth Stoner sold 4,236 shares of the business’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $25.00, for a total transaction of $105,900.00. Following the sale, the director now owns 39,745 shares in the company, valued at approximately $993,625. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Craig A. Wheeler sold 37,228 shares of the company’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $28.51, for a total transaction of $1,061,370.28. The disclosure for this sale can be found here. In the last 90 days, insiders sold 271,235 shares of company stock worth $7,361,311. 3.40% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. grew its position in Momenta Pharmaceuticals by 362.0% during the 4th quarter. Meeder Asset Management Inc. now owns 2,421 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,897 shares in the last quarter. Smith Asset Management Group LP acquired a new stake in shares of Momenta Pharmaceuticals in the fourth quarter worth $62,000. Nisa Investment Advisors LLC grew its holdings in shares of Momenta Pharmaceuticals by 611.9% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,770 shares of the biotechnology company’s stock valued at $94,000 after buying an additional 4,100 shares in the last quarter. Teza Capital Management LLC acquired a new position in Momenta Pharmaceuticals during the fourth quarter valued at $228,000. Finally, Victory Capital Management Inc. lifted its stake in Momenta Pharmaceuticals by 22.0% in the 4th quarter. Victory Capital Management Inc. now owns 14,083 shares of the biotechnology company’s stock worth $409,000 after acquiring an additional 2,541 shares in the last quarter. 97.03% of the stock is owned by hedge funds and other institutional investors.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
Recommended Story: What is Green Investing?
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.